LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the drug pipeline for the atypical hemolytic uremic syndrome. The report includes a detailed analysis of the ...

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Atypical Hemolytic Uremic Syndrome pipeline constitutes 5+ key companies continuously working towards developing 5+ ...

Please provide your email address to receive an email when new articles are posted on . The FDA today granted fast track status to OMS721 — a complement inhibitor — for the treatment of patients with ...

- At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Atypical HUS affects both adults and children and many ...

SEATTLE, Wash.--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that data from the dose-ranging stage of the Phase 2 clinical trial evaluating OMS721 in the treatment of atypical ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Atypical hemolytic uremic syndrome is a ...

Alexion announced that results from its Phase 2 study of Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy. The ...

July 23 -- WEDNESDAY, July 22 (HealthDay News) -- Mutations in a protein called thrombomodulin, which is involved in blood clotting and preventing cell damage, may be the cause of some atypical HUS, a ...

Atypical haemolytic uremic syndrome (aHUS) is an uncommon, yet potentially life‐threatening disorder predominantly characterised by dysregulation of the alternative complement pathway. Unlike the more ...

Hemolytic uremic syndrome (HUS) is a condition that affects the blood vessels in your kidneys. When the vessels are damaged, they form clots that block the kidney's regular filtering system, leading ...